As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of iTeos Therapeutics, Inc. The largest reported stake is Tang Capital Management, LLC's, at 100%. 5 filings are on record since July 22, 2025 (Schedule 13D/A, September 3, 2025).
Sell to companies like iTeos Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Ridgeback Capital Investments L.P. · Percent: 0% · SCHEDULE 13G/A
- · Holder: Tang Capital Management, LLC · Percent: 100% · SCHEDULE 13D/A
- · Holder: Biotechnology Value Fund L P · Percent: 0% · SCHEDULE 13G/A
- · Holder: Ridgeback Capital Investments L.P. · Percent: 5.1% · SCHEDULE 13G
- · Holder: Tang Capital Management, LLC · Percent: 9.99% · SCHEDULE 13D/A
iTeos Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2025-07-22. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Tang Capital Management, LLC | 100% | 10,000 | SCHEDULE 13D/A, 2025-09-03 | 2025-08-29 |
| Ridgeback Capital Investments L.P. | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Biotechnology Value Fund L P | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind iTeos Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on iTeos Therapeutics, Inc. and the records around it.
Companies that share a holder
- Ridgeback Capital Investments L.P. also filed stake reports on 3 other companies: Replimune Group, Inc. (Aug 2026), Lenz Therapeutics, Inc. (Feb 2026), Semler Scientific, Inc. (Nov 2025)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Watch iTeos Therapeutics, Inc.
Get an email when iTeos Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on iTeos Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on iTeos Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on iTeos Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Tang Capital Management, LLC
Item 4 of the Schedule 13D is amended by adding the following: Closing of the Merger: As previously disclosed, each of Concentra, the Issuer and Merger Sub entered into the Merger Agreement, which provides for an Offer by Merger Sub for all of the Issuer's Common Stock. The Offer commenced on August 1, 2025. On August 29, 2025, the Offer expired and Merger Sub accepted for purchase a total of 32,226,407 shares tendered and not withdrawn, representing approximately 72.17% of the total shares of the Issuer issued and outstanding. Following the expiration of the Offer, Merger Sub merged with and into the Issuer on August 29, 2025, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into the right to receive the Offer Price, with the Issuer surviving as a wholly owned subsidiary of Concentra.Item 4 of the SCHEDULE 13D/A filed 2025-09-03
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-22 | Tang Capital Management, LLC | 9.99% | SCHEDULE 13D/A |
| 2025-07-25 | Ridgeback Capital Investments L.P. | 5.1% | SCHEDULE 13G |
| 2025-08-14 | Biotechnology Value Fund L P | 0% | SCHEDULE 13G/A |
| 2025-09-03 | Tang Capital Management, LLC | 100% | SCHEDULE 13D/A |
| 2025-11-14 | Ridgeback Capital Investments L.P. | 0% | SCHEDULE 13G/A |
Questions about who owns iTeos Therapeutics, Inc.
Who owns iTeos Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of iTeos Therapeutics, Inc.: Tang Capital Management, LLC (100%, Schedule 13D/A, filed 2025-09-03).
When did Tang Capital Management, LLC buy into iTeos Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Tang Capital Management, LLC on this page is the Schedule 13D/A, filed 2025-07-22, reporting 9.99%; its latest, Schedule 13D/A filed 2025-09-03, reports 100%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for iTeos Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.